Literature DB >> 1355019

Effects of acute febrile infectious diseases on the oral pharmacokinetics and effects of nitrendipine enantiomers and of bisoprolol.

P A Soons1, C Grib, D D Breimer, W Kirch.   

Abstract

In 2 longitudinal studies with 10 patients each, the stereoselective pharmacokinetics of nitrendipine and the pharmacokinetics of racemic (rac) bisoprolol (both 20mg orally) were investigated during acute febrile infectious diseases and at least 6 weeks later in the healthy state. The area under the plasma concentration-time curve (AUC) and peak plasma concentration (Cmax) of rac-nitrendipine were increased in the infectious state by 89% [95% confidence interval (CI): 24 to 187%] and 95% (95% CI: 22 to 209%), respectively. Similar increases were observed for both S- and R-nitrendipine. Nitrendipine exhibited stereoselective pharmacokinetics in both the healthy state and the infectious state, but the mean ratios of S:R AUC values [healthy: 1.79 (95% CI: 1.36 to 2.11); infectious: 1.87 (95% CI: 1.62 to 2.11)] were not different. The elimination half-life, protein binding and haemodynamic effects of nitrendipine also did not differ between the infectious and the healthy state. The mechanism for the disease effects may be related to suppression of hepatic cytochrome P450 activity by mediators of inflammatory reactions. On the other hand, none of the pharmacokinetic parameters, including nonrenal clearance, of rac-bisoprolol was changed during febrile infectious disease, indicating specificity in the effects of acute febrile disease on oxidative drug metabolism.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355019     DOI: 10.2165/00003088-199223030-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  39 in total

1.  Toxic reaction to phenytoin following a viral infection.

Authors:  M Levine; M W Jones
Journal:  Can Med Assoc J       Date:  1983-06-01       Impact factor: 8.262

2.  Enantioselective determination of felodipine and other chiral dihydropyridine calcium entry blockers in human plasma.

Authors:  P A Soons; M C Roosemalen; D D Breimer
Journal:  J Chromatogr       Date:  1990-06-29

3.  Quinine disposition during malaria and during induced fever.

Authors:  G M Trenholme; R L Williams; K H Rieckmann; H Frischer; P E Carson
Journal:  Clin Pharmacol Ther       Date:  1976-04       Impact factor: 6.875

4.  Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae.

Authors:  W R Brian; M A Sari; M Iwasaki; T Shimada; L S Kaminsky; F P Guengerich
Journal:  Biochemistry       Date:  1990-12-25       Impact factor: 3.162

5.  Effects of influenza virus vaccine on hepatic drug metabolism.

Authors:  C G Meredith; C D Christian; R F Johnson; R Troxell; G L Davis; S Schenker
Journal:  Clin Pharmacol Ther       Date:  1985-04       Impact factor: 6.875

6.  Cytochrome P-450-catalyzed dehydrogenation of 1,4-dihydropyridines.

Authors:  F P Guengerich; R H Böcker
Journal:  J Biol Chem       Date:  1988-06-15       Impact factor: 5.157

7.  Interaction of bisoprolol with cimetidine and rifampicin.

Authors:  W Kirch; I Rose; I Klingmann; J Pabst; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Drug metabolism in experimental tuberculosis: I. Changes in hepatic and pulmonary monooxygenase activities due to infection.

Authors:  J K Batra; T A Venkitasubramanian; H G Raj
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Apr-Jun       Impact factor: 2.441

9.  Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans.

Authors:  K U Bühring; H Sailer; H P Faro; G Leopold; J Pabst; A Garbe
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

10.  Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay.

Authors:  A Wellstein; D Palm; G G Belz; G Leopold; K U Bühring; J Pabst
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

View more
  3 in total

1.  Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies.

Authors:  B G Reigner; H A Welker
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

2.  Bupivacaine kinetics during hyperthermia in rats.

Authors:  B Bruguerolle; X Roucoules; L Attolini; A M Lorec
Journal:  Can J Anaesth       Date:  1994-03       Impact factor: 5.063

Review 3.  Pharmacokinetic drug interactions with antimicrobial agents.

Authors:  J G Gillum; D S Israel; R E Polk
Journal:  Clin Pharmacokinet       Date:  1993-12       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.